FDA
-
-
-
-
-
-
-
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
-
-
-
-
-
-
-
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
-
-
-
-
-
-
-
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
-
-
-
-
-
-
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
326,257 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

